Enhanced donor screening for faecal microbial transplantation during COVID-19
Gut
.
2021 Nov;70(11):2219-2220.
doi: 10.1136/gutjnl-2021-324593.
Epub 2021 Mar 31.
Authors
Seema Nair Parvathy
1
2
,
John G Lenehan
3
4
,
Ricardo Fernandes
3
4
,
Susan M Poutanen
5
6
,
Susy Hota
7
8
,
Saman Maleki Vareki
4
9
10
,
Michael Silverman
11
2
10
Affiliations
1
Infectious Diseases, St.Joseph's Health Care, London, Ontario, Canada.
2
Infectious Diseases, Medicine, Western University, London, Ontario, Canada.
3
Division of Medical Oncology, Department of Oncology, Western University, London, Ontario, Canada.
4
Division of Experimental Oncology, Department of Oncology, Western University, London, Ontario, Canada.
5
Departments of Laboratory Medicine and Pathobiology and Medicine, University of Toronto, Toronto, Ontario, Canada.
6
Department of Microbiology & Division of Infectious Diseases, University Health Network and Sinai Health, Toronto, Ontario, Canada.
7
Infection Prevention and Control Department, University Health Network, Toronto, Ontario, Canada.
8
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
9
Departments of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
10
Lawson Health Research Institute, London, Ontario, Canada.
11
Infectious Diseases, St.Joseph's Health Care, London, Ontario, Canada Michael.Silverman@sjhc.london.on.ca.
PMID:
33789964
PMCID:
PMC8515114
DOI:
10.1136/gutjnl-2021-324593
No abstract available
Keywords:
COVID-19; cancer; infectious diarrhoea; infectious disease.
Publication types
Letter
Comment
MeSH terms
COVID-19*
Clostridioides difficile*
Donor Selection
Fecal Microbiota Transplantation
Humans
SARS-CoV-2